Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VROOM
ISRCTN11442263Phase 4Completed
- Sponsor
- University of Nottingham
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of methotrexate in Inflammatory Polyarthritis, rheumatoid arthritis (RA), psoriasis and 5 more (2 arms), sponsored by University of Nottingham. Primary endpoint: Anti-spike receptor binding domain antibody level at 4 weeks. Started Sep 2021; status: completed.
02
Drugs
methotrexate
03
Conditions
Inflammatory Polyarthritisrheumatoid arthritis (RA)psoriasisspondyloarthritis (SpA)reactive arthritis
Beyond the preview
Go deeper on ISRCTN11442263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11442263.